Brain neurotrophic factor (BDNF) is one of the key indicators of neurogenesis and neuroplasticity. The concentration of BDNF in the blood is positioned as a potential biomarker of the development and dynamics of neuropsychiatric diseases. However, the extent to which its concentration in the blood reflects its content in the brain is not clear; a literature analysis on this matter has not been performed. This review provides basic information about the biological role, content and regulation of BDNF in the body (chapter I), about the concentration of BDNF in the blood in neuropsychiatric diseases (chapter II), and analyzes the correlation of BDNF content in the brain and blood (chapter III, the main one). In 5 out of 6 studies on intact animals identified as a result of the literature search, a statistically significant positive correlation between the concentration of BDNF in the brain and blood is reported. However, the correlation coefficient is variable and generally not high - from 0.40 to 0.83. There were no during-life studies performed in human. Some post-mortem studies have reported a significant association between BDNF indices values in the brain and in the periphery. Thus, the question of the extent to which BDNF in the blood is diagnostically valuable remains unanswered.
1 February 2005 in Bulletin of Experimental Biology and Medicine
The influence of the antitumor drugs, cyclophosphamide (CPA) and nitrosomethylurea (NMU) on the activity of lysosomal cysteine proteases cathepsin B and L in tumor tissue has been investigated using CPA-sensitive (LS) and CPA-resistant mouse lymphosarcomas (RLS). (These drugs exhibit high and low antitumor efficiency towards LS and RLS mouse lymphosarcomas, respectively). Regression or reduction in the growth rate of LS and RLS lymphosarcomas caused by CPA or NMU administration was accompanied by the increase in the activity of cysteine proteases cathepsin B and L in the tumor tissue. The increase of cathepsin B and L activity in tumor tissue correlated with the therapeutic effect of these drugs. Data obtained suggest that activity of cathepsin B and L in tumor tissue has a prognostic significance for the estimation of the effectiveness of antitumor therapy.